>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>MS023 dihydrochloride

MS023 dihydrochloride

Catalog No.GC36655

MS023 디히드로클로라이드는 PRMT1, PRMT3, PRMT4, PRMT6 및 PRMT8에 대해 IC50이 30, 119, 83, 4 및 5 nM인 인간 I형 단백질 아르기닌 메틸트랜스퍼라제(PRMT) 억제제의 강력하고 선택적인 세포 활성 억제제입니다. 각기.

Products are for research use only. Not for human use. We do not sell to patients.

MS023 dihydrochloride Chemical Structure

Cas No.: 1992047-64-9

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$73.00
재고 있음
2mg
US$70.00
재고 있음
5mg
US$93.00
재고 있음
10mg
US$167.00
재고 있음
25mg
US$306.00
재고 있음
50mg
US$565.00
재고 있음
100mg
US$1,020.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MS023 dihydrochloride is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively[1]. IC50: 30 nM (PRMT1), 119 nM (PRMT3), 83 nM (PRMT4), 4 nM (PRMT6), 5 nM (PRMT8)[1]

MS023 (1-1000 nM; 48 hours) inhibits PRMT1 methyltransferase activity in MCF7 cells[1]. MS023(1-1000 nM; 20 hours) inhibits PRMT6 methyltransferase activity in HEK293 cells[1]. Western Blot Analysis[1] Cell Line: MCF7 and HEK293 cells

[1]. Eram MS, et al. A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. ACS Chem Biol. 2016 Mar 18;11(3):772-81.

리뷰

Review for MS023 dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MS023 dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.